Hydroxyurea, a new drug, does not seem to be effective in reducing the risk of recurrent stroke in children with sickle cell anemia and iron overload.
The National Heart, Lung, and Blood Institute (NHLBI), US, said it was giving up a major trial as there was no evidence that the drug could be any better than the existing treatment.
The 26[-site trial, Stroke With Transfusions Changing to Hydroxyurea, or SWiTCH, studied 133 participants between the ages of 5 and 18 who had already experienced a stroke. All had been receiving the standard treatment of blood transfusions for at least 18 months and high levels of iron before entering the study. Without further preventive measures, these children were at high risk of another stroke as well as life-threatening conditions due to iron overload.
The study tested whether the drug known to prevent complications of sickle cell disease in adults, was as effective as transfusions, the standard therapy, in reducing the risk of recurrent strokes. Hydroxyurea is the only FDA-approved drug for treating sickle cell anemia.
The study also compared two approaches to remove excess iron, a consequence of regular blood transfusions. Participants who continued to receive transfusion therapy were given the standard oral iron-removal drug deferasirox, and participants who were switched to hydroxyurea underwent regular phlebotomy (blood removal) to eliminate excess iron that had accumulated from their earlier transfusions.
Phlebotomy did not reduce liver iron better than deferasirox therapy. Analysis of the available data indicated that continuing the trial was unlikely to show that phlebotomy would provide a greater benefit than deferasirox to control iron accumulation. Without the ability to provide benefits for the management of liver iron, the potential risks of continuing study treatments were no longer warranted.
"Protecting our participants is an important factor in determining whether to stop a trial," said Susan B. Shurin, MD, acting director of the NHLBI, who is a board-certified hematologist and pediatrician. The NHLBI is part of the National Institutes of Health. "When an experimental treatment fails to meet its predetermined goals, it is best to return participants to standard treatment as soon as possible."
By the time the trial was halted, approximately one-third of participants had completed the study, during which they were treated and monitored for 30 months. At enrollment, participants were randomly assigned to either the alternative or the standard treatment group. The study's independent Data and Safety Monitoring Board (DSMB) reviewed interim results from the trial and recommended stopping the study. The NHLBI accepted the recommendation and stopped the study on May 6.
The DSMB noted that no strokes occurred in the 66 participants who received the standard therapy of blood transfusions and deferasirox. In contrast, seven strokes occurred in the group of 67 participants who received hydroxyurea with phlebotomy. Study participants and their families have been contacted, and they will discuss future care options with their health care providers.
NHLBI-supported research has shown that hydroxyurea helps prevent pain crises, a common complication of the disease, and some lung complications in adults. Preliminary studies have suggested that hydroxyurea might also help reduce the risk of stroke recurrence in children with sickle cell disease. Patients currently taking hydroxyurea should continue taking the treatment as prescribed and should talk to their primary care provider if they have any concerns, Shurin advised.
Regular blood transfusions greatly reduce the number of strokes in at-risk children with sickle cell disease. Because repeated transfusions cause side effects such as buildup of excess iron in the body, researchers hope to find more effective and safer ways to reduce stroke risk in young patients. Iron overload can damage organs and lead to cirrhosis (a liver condition), poor growth and development, and heart rhythm disturbances.
"These kinds of studies are so important to finding new treatments and confirming that current standards of care are the best available options," Shurin explained. "The field of medicine would not advance without the help of those willing to participate in clinical research. We are grateful to these young patients and their parents for helping advance treatments of sickle cell disease. Their contributions will help us find other approaches to preventing complications of sickle cell disease."
About 10 percent of children with sickle cell disease suffer a stroke. Having experienced one, they are at high risk of having another unless they receive preventive treatment.
Sickle cell disease affects more than 70,000 Americans. It is seen mostly in persons of African descent, but also in individuals of Middle Eastern, Mediterranean, Central and South American, and Asian Indian heritage. New therapies have helped patients live into middle age and older. Sickle cell disease involves an altered gene that produces abnormal hemoglobin, the protein that carries oxygen in the blood. Red blood cells with sickle hemoglobin become C-shaped, stiff, and sticky when they release the oxygen they carry. The deformed cells impede blood flow, causing severe pain and organ damage.
The study was scheduled to run until 2012.